Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.38 |
| ▸ | PNP | P00491 | 2/20 | 0.38 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.37 |
| ▸ | XDH | P47989 | 3/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.34 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26155922 | 0.82 | PNP (0.48) | PNPNUDT1CSNK2A1 | |
| SCHEMBL8591402 | 0.81 | FGFR1 (0.51) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL11567738 | 0.80 | FGFR1 (0.38) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL16513137 | 0.80 | GDA (0.64) | GDAFGFR1FGFR2FGFR3 | |
| SCHEMBL9275474 | 0.77 | XDH (0.38) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL6270959 | 0.76 | FYN (0.52) | CSNK2A1 | |
| SCHEMBL16513140 | 0.76 | MAPT (0.50) | FGFR1FGFR2PNP | |
| SCHEMBL22885 | 0.75 | GDA (0.68) | GDAPNPXDH | |
| SCHEMBL5133744 | 0.75 | XDH (0.39) | GDAFGFR1FGFR2PNPFGFR3 | |
| SCHEMBL4384740 | 0.75 | XDH (0.67) | PNPXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 687 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | Arcturus, Inc. (US) | 2021-04-06 | — | — | US | claimed |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | ARCTURUS THERAPEUTICS, INC. | 2020-02-06 | — | — | US | claimed |
| EP-2179039-B1 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES | ZOETIS BELGIUM S A (BE) | 2018-10-31 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| EP-2451475-A2 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | Novartis AG (CH) | 2012-05-16 | — | — | EP | claimed |
| US-20110300205-A1 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | claimed |
| WO-2011005799-A2 | SELF REPLICATING RNA MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2011-01-13 | — | — | WO | claimed |
| CN-101821392-A | RNA sequence motifs inducing specific immunomodulatory properties in a defined internucleotide linkage environment | COLEY PHARM GMBH | 2010-09-01 | — | — | CN | claimed |
| WO-2009022216-A2 | RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES | COLEY PHARMACEUTICAL GMBH (US) | 2009-02-19 | — | — | WO | claimed |
| WO-2008033432-A2 | IMMUNE MODULATION BY CHEMICALLY MODIFIED RIBONUCLEOSIDES AND OLIGORIBONUCLEOTIDES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-1899467-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceutical GmbH (DE) | 2008-03-19 | — | — | EP | claimed |
| CN-1973821-A | Medicine composition containing both anticancer medicine and its synergist | SHANDONG LANJIN BIOENGINEERING (CN) | 2007-06-06 | — | — | CN | claimed |
| WO-2006116458-A2 | MODIFIED OLIGORIBONUCLEOTIDE ANALOGS WITH ENHANCES IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2006-11-02 | — | — | WO | claimed |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2006-10-26 | — | — | US | claimed |
| US-20050239727-A1 | for use in cosmetics, drugs | SILDEHA SWISS SA (CH) | 2005-10-27 | — | — | US | claimed |
| EP-1525224-A1 | HYALURONIC ACID DERIVATIVES | Jasper Ltd. Liability Co. (US) | 2005-04-27 | — | — | EP | claimed |
| EP-1518854-A1 | Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2004013182-A1 | HYALURONIC ACID DERIVATIVES | JASPER LTD LIABILITY CO. (US) | 2004-02-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239727-A1 | for use in cosmetics, drugs | HINT1, NUDT1, NNT | GDA 50/4885FGFR1 761/4885FGFR2 1390/4885 |
| US-20200040026-A1 | TRINUCLEOTIDE MRNA CAP ANALOGS | RNGTT, RNMT, NSUN2 | GDA 821/4885FGFR1 4273/4885FGFR2 4657/4885 |
| US-10968248-B2 | Trinucleotide mRNA cap analogs | RNGTT, RNMT, NSUN2 | GDA 821/4885FGFR1 4273/4885FGFR2 4657/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | GDA 1197/4885FGFR1 547/4885FGFR2 658/4885 |
| US-20060241076-A1 | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity | TLR3, TLR8, TLR9 | GDA 299/4885FGFR1 934/4885FGFR2 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.